Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of ILS 22.25 million. The enterprise value is -3.45 million.
Market Cap | 22.25M |
Enterprise Value | -3.45M |
Important Dates
The last earnings date was Thursday, May 15, 2025.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 542.78 million shares outstanding. The number of shares has increased by 37.04% in one year.
Current Share Class | 542.78M |
Shares Outstanding | 542.78M |
Shares Change (YoY) | +37.04% |
Shares Change (QoQ) | -99.36% |
Owned by Insiders (%) | 0.30% |
Owned by Institutions (%) | 1.89% |
Float | 536.25M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 0.18 |
P/TBV Ratio | 1.24 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 0.24 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.00.
Current Ratio | 2.72 |
Quick Ratio | 2.57 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -430.17 |
Financial Efficiency
Return on equity (ROE) is -12.40% and return on invested capital (ROIC) is -15.07%.
Return on Equity (ROE) | -12.40% |
Return on Assets (ROA) | -12.83% |
Return on Invested Capital (ROIC) | -15.07% |
Return on Capital Employed (ROCE) | -23.58% |
Revenue Per Employee | n/a |
Profits Per Employee | -1.63M |
Employee Count | 9 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.05% in the last 52 weeks. The beta is -0.16, so Purple Biotech's price volatility has been lower than the market average.
Beta (5Y) | -0.16 |
52-Week Price Change | -84.05% |
50-Day Moving Average | 4.64 |
200-Day Moving Average | 6.71 |
Relative Strength Index (RSI) | 40.47 |
Average Volume (20 Days) | 689,276 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | -230,857 |
Operating Income | -28.83M |
Pretax Income | -14.72M |
Net Income | -14.64M |
EBITDA | -28.72M |
EBIT | -28.83M |
Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 26.39 million in cash and 510,120 in debt, giving a net cash position of 25.88 million or 0.05 per share.
Cash & Cash Equivalents | 26.39M |
Total Debt | 510,120 |
Net Cash | 25.88M |
Net Cash Per Share | 0.05 |
Equity (Book Value) | 121.74M |
Book Value Per Share | 46.18 |
Working Capital | 17.71M |
Cash Flow
Operating Cash Flow | -41.94M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -37.04% |
Shareholder Yield | n/a |
Earnings Yield | -65.77% |
FCF Yield | n/a |
Stock Splits
The last stock split was on January 6, 2019. It was a reverse split with a ratio of 0.05.
Last Split Date | Jan 6, 2019 |
Split Type | Reverse |
Split Ratio | 0.05 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |